NCT06920212Active, not recruiting
Clinical Safety and Efficacy of Fecal Microbiota Transplantation (FMT) in the Treatment of Alzheimer's Disease
Clinical Safety and Efficacy of FMT in the Treatment of Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 9 Apr 2025
Brief summary (registry, in English)
To investigate the clinical safety and efficacy of FMT in AD patients, as well as the changes in the gut microbiota of AD patients before and after FMT.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 31 Mar 2025
- Start date
- 1 Oct 2024
- Primary completion date
- 31 Oct 2025
- Lead sponsor
- Shanghai 10th People's Hospital
- Diseases
- Alzheimer disease
- NCT number
- NCT06920212
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Oct 2024 to the primary completion date, 31 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- patients who had participated in clinical drug trials within the past 30 days or consumed folate and vitamin B12 at doses exceeding twice the recommended intake were ineligible.
Other illness
- with conditions mimicking AD symptoms-such as normal pressure hydrocephalus, vascular dementia (VD or VaD);
- Parkinson's disease dementia (PDD)-were also excluded;
Other
- Patients were excluded if they had severe visual, hearing, or language impairments;
- Tumors;
- hepatic/renal dysfunction.
Who the study is looking for
- The patients (aged 50-85 years) exhibited cognitive decline persisting for over six months;
- Primarily characterized by recent memory impairment and accompanied by reduced daily living abilities;
- MMSE scores ranging from 3 to 26;
- MRI findings revealed atrophy in the medial temporal lobe, hippocampus, and cerebral cortex, along with widened sulci and fissures.
Age in the registry: 50 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Le Wang Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.